Five-Year Evaluation Coverage, 2026-27 to 2030-31
| Program | Title of Planned Evaluations | Planned Year of Approval | Estimated 2026-27 Program Spending Covered by Evaluation | Total 2026-27 Planned Program Spending |
|---|---|---|---|---|
Patented Medicine Price Monitoring Program |
No planned evaluation |
N/A |
N/A |
$11,303,616 |
Pharmaceutical Trends Program |
No planned evaluation |
N/A |
N/A |
$2,364,501 |
Internal Services |
No planned evaluation |
N/A |
N/A |
$3,544,076 |
Additional explanatory note: No planned evaluations to 2030-31 given transition from amendments to Patented Medicine Regulations and new Guidelines. The evaluation need will be reassessed each year.